## Macquarie **Equities Research**



## The Global FIG Specialist

#### **INDIA**

Recommendation pattern						
INR	Ticker	Rec	CMP	TP		
Private banks						
Axis Bank	AXSB IN	Restricted	808	NA		
HDFC Bank	HDFCB IN	OP	427	615		
ICICI Bank	ICICIBC IN	N	685	920		
Kotak Bank	KMB IN	OP	431	550		
YES Bank	YES IN	OP	239	380		
PSU banks						
Bank of Baroda	BOB IN	N	665	800		
Bank of India	BOI IN	UP	266	275		
Canara Bank	CBK IN	UP	365	370		
PNB	PNB IN	UP	781	880		
SBI	SBIN IN	UP	1,619	1,700		
Union Bank	UNBK IN	N	170	225		
Prices as of Dec	30 2011					

Prices as of Dec 30, 2011

Source: Bloomberg, Macquarie Research, January 2012

#### **Capital ratios**

		Core			
(As of FY11)	Tier-I	Tier-I	CE	Leverage	CAR
Private Banks					
Axis Bank	9.4%	9.2%	8.9%	7.6%	12.7%
HDFC Bank	12.2%	12.4%	12.4%	8.7%	16.2%
ICICI Bank	13.2%	11.9%	11.8%	12.4%	19.5%
Kotak Bank	18.1%	18.1%	17.5%	14.2%	19.5%
Yes Bank	9.7%	8.3%	7.4%	7.1%	16.5%
PSU Banks					
BOB	10.0%	9.1%	6.9%	5.9%	14.5%
BOI	8.3%	7.8%	4.9%	4.9%	12.2%
PNB	8.4%	7.5%	5.8%	5.5%	12.4%
SBI	7.8%	7.4%	5.2%	6.9%	12.0%
Union Bank	8.7%	7.9%	5.5%	5.2%	13.0%

Note: Leverage ratio is calculated as Tier-I capital as a percentage of assets. The actual leverage ratio calculation is yet to be prescribed by RBI and could differ. We have defined core tier-1 as tier-1 excluding hybrids. CE stands for common equity.

Source: Company data, Macquarie Research, January

#### Analyst(s)

Suresh Ganapathy, CFA

+91 22 6720 4078 suresh.ganapathy@macquarie.com **Mudit Painuly** 

+91 22 6720 4083 Yuvaraj Bhole

+91 22 6720 4098 yuvaraj.bhole@macquarie.com

mudit.painuly@macquarie.com

2 January 2012

Macquarie Capital Securities India (Pvt)

# India Banks

# Basel - III Draft guidelines - Be prepared for structurally lower ROE

#### **Event**

Basel – III draft regulations – Increased capital requirements to drag down ROE: RBI on Friday released draft regulations of Basel-III for banks in India. We believe the revised onerous capital requirements are likely to structurally bring down leverage ratios and ROEs could be affected to the tune of 300bps over the longer term.

#### **Impact**

- So what do the regulations propose? RBI's draft guidelines talk about the following - i) Minimum Tier-I ratio to be at 7% with common equity ratio to be atleast 5.5% and total CAR to be at 9%. The balance in Tier I i.e. 1.5% could include hybrid instruments. ii) Additional capital conservation buffer (CCB) in the form of common equity at 250bps. Hence the total capital requirements would be 11.5% of RWA. RBI has also specified a minimum Tier-I leverage ratio of 5% (exact calculation of leverage ratio has not been specified). The guidelines on liquidity standards will be issued separately.
- So what has changed? Currently banks in India have to maintain a CAR of 9% with minimum Tier-I of 6% and there are no prescriptions for common equity. There is also no CCB or leverage ratio limit. In general capital requirements have been increased which anyways was not unexpected. Secondly Tier-I and Tier-II capital could include hybrids according to the draft regulations; however these hybrids have now been strengthened with respect to their loss absorbency capacity. The current hybrid instruments largely don't comply with the additional requirements imposed and hence would be grandfathered over a period of time in our view.
- Implementation timeline stricter than actual Basel-III: Implementation of Basel-III in India is proposed to begin on Jan 1st 2013 and fully implemented by March 31st 2017 vs. the January 1st 2019 deadline proposed by Basel Committee. Every year beginning from 1st Jan 2013, CCB has to be increased by 0.625%. The grandfathering of various innovative/hybrid capital instruments that exist currently and doesn't meet the qualifying criteria proposed will begin from 1st Jan 2013 going all the way till 1st Jan 2022.
- Who gets impacted the most and what is the likely impact? We have always argued that Basel-III would be more an issue of growth than solvency for Indian banks and the onerous capital requirements imposed could be a challenge especially for PSU banks as they are at the mercy of Government with regards to their capital needs. Our analysis suggests that currently most of the banks in India already are at Basel-III levels of capital adequacy (without including the CCB) and leverage ratio is above 5%. However frequent dilutions will be equity required to support growth and also simultaneously maintain the CAR levels and capital buffers. The ones which have the lowest common equity and capital ratios amongst our coverage universe are SBI, BOI and Union Bank. Private Banks fare much better with YES Bank having the lowest common equity ratio.

#### Outlook

We maintain our cautious stance on the sector.

Please refer to the important disclosures and analyst certification on inside back cover of this document, or on our website www.macquarie.com.au/disclosures.

Macquarie Research India Banks

Fig 1 Capital position of banks - PSUs walking a tightrope and will have to buckle up

(As of FY11)	Tier-I	Core Tier-I	Common Equity	Tier-I Leverage	Capital Adequacy
Private Banks					
Axis Bank	9.4%	9.2%	8.9%	7.6%	12.7%
HDFC Bank	12.2%	12.2%	12.2%	8.7%	16.2%
ICICI Bank	13.2%	11.9%	11.8%	12.4%	19.5%
Kotak Bank	18.1%	18.1%	17.5%	14.2%	19.5%
Yes Bank	9.7%	8.3%	7.4%	7.1%	16.5%
PSU Banks					
BOB	10.0%	9.1%	6.9%	5.9%	14.5%
Bank of India	8.3%	7.8%	4.9%	4.9%	12.2%
PNB	8.4%	7.5%	5.8%	5.5%	12.4%
SBI	7.8%	7.4%	5.2%	6.9%	12.0%
Union Bank	8.7%	7.9%	5.5%	5.2%	13.0%

Note: Leverage ratio is calculated as Tier-I capital as a percentage of assets. The actual leverage ratio calculation is yet to be prescribed by RBI and could differ. We have defined core tier-1 as tier-1 excluding hybrids

Source: Company data, Macquarie Research, January 2012

Fig 2 Capital requirements for Basel III

Sr. No	p. Regulatory Capital	% of RWAs
(i)	Minimum Common Equity Tier 1 ratio	5.5%
(ii)	Capital conservation buffer (comprised of Common Equity)	2.5%
(iii)	Minimum Common Equity Tier 1 ratio plus capital conservation buffer [(i)+(ii)]	8.0%
(iv)	Additional Tier 1 Capital	1.5%
(v)	Minimum Tier 1 capital ratio [(i) +(iv)]	7.0%
(vi)	Tier 2 capital	2.0%
(vii)	Minimum Total Capital Ratio (MTC) [(v)+(vi)]	9.0%
(viii)	Minimum Total Capital Ratio plus capital conservation buffer [(vii)+(ii)]	11.5%
Sourc	e: RBI, Macquarie Research, January 2012	

Fig 3 Transitional Arrangements for Scheduled Commercial Banks

	As a percentage of Risk Weighted Assets (RWAs)					
Minimum capital ratios	Jan 1, 2013	Mar 31, 2014	Mar 31, 2015	Mar 31, 2016	Mar 31, 2017	
Minimum Common Equity Tier 1 (CET1)	4.5%	5%	5.5%	5.5%	5.5%	
Capital conservation buffer (CCB)		0.625%	1.25%	1.875%	2.5%	
Minimum CET1+ CCB	4.5%	5.625%	6.75%	7.375%	8%	
Minimum Tier 1 capital	6%	7%	7%	7%	7%	
Minimum Total Capital*	9%	9%	9%	9%	9%	
Minimum Total Capital +CCB	9%	9.625%	10.25%	10.875%	11.5%	
Phase-in of all deductions from CET1 (%)	40%	60%	80%	100%	100%	

Note: \* The difference between the minimum total capital requirement of 9% and the Tier 1 requirement can be met with Tier 2 and higher forms of capital.

Source: RBI, Macquarie Research, January 2012

2 January 2012 2

Macquarie Research India Banks

#### Important disclosures:

#### **Recommendation definitions**

#### Macquarie - Australia/New Zealand

Outperform – return >3% in excess of benchmark return Neutral – return within 3% of benchmark return Underperform – return >3% below benchmark return

Benchmark return is determined by long term nominal GDP growth plus 12 month forward market dividend yield

#### Macquarie - Asia/Europe

Outperform – expected return >+10% Neutral – expected return from -10% to +10% Underperform – expected return <-10%

#### Macquarie First South - South Africa

Outperform – expected return >+10% Neutral – expected return from -10% to +10% Underperform – expected return <-10%

#### Macquarie - Canada

Outperform – return >5% in excess of benchmark return Neutral – return within 5% of benchmark return Underperform – return >5% below benchmark return

#### Macquarie - USA

Outperform (Buy) – return >5% in excess of Russell 3000 index return

Neutral (Hold) – return within 5% of Russell 3000 index return

Underperform (Sell) – return >5% below Russell 3000 index return

#### Volatility index definition\*

This is calculated from the volatility of historical price movements.

Very high-highest risk – Stock should be expected to move up or down 60–100% in a year – investors should be aware this stock is highly speculative.

**High** – stock should be expected to move up or down at least 40–60% in a year – investors should be aware this stock could be speculative.

**Medium** – stock should be expected to move up or down at least 30–40% in a year.

**Low-medium** – stock should be expected to move up or down at least 25–30% in a year.

**Low** – stock should be expected to move up or down at least 15–25% in a year.

\* Applicable to Australian/NZ/Canada stocks only

Recommendations – 12 months

**Note:** Quant recommendations may differ from Fundamental Analyst recommendations

#### **Financial definitions**

All "Adjusted" data items have had the following adjustments made:

Added back: goodwill amortisation, provision for catastrophe reserves, IFRS derivatives & hedging, IFRS impairments & IFRS interest expense Excluded: non recurring items, asset revals, property revals, appraisal value uplift, preference dividends & minority interests

**EPS** = adjusted net profit / efpowa\*

ROA = adjusted ebit / average total assets

ROA Banks/Insurance = adjusted net profit /average total assets

ROE = adjusted net profit / average shareholders funds Gross cashflow = adjusted net profit + depreciation \*equivalent fully paid ordinary weighted average number of shares

All Reported numbers for Australian/NZ listed stocks are modelled under IFRS (International Financial Reporting Standards).

#### Recommendation proportions – For quarter ending 30 September 2011

	AU/NZ	Asia	RSA	USA	CA	EUR
Outperform	57.35%	65.88%	56.94%	46.54%	74.68%	47.85% (for US coverage by MCUSA, 11.63% of stocks covered are investment banking clients)
Neutral	31.99%	20.68%	31.94%	50.00%	23.42%	34.66% (for US coverage by MCUSA, 9.30% of stocks covered are investment banking clients)
Underperform	10.66%	13.45%	11.11%	3.46%	1.90%	17.49% (for US coverage by MCUSA, 0.47% of stocks covered are investment banking clients)

#### **Company Specific Disclosures:**

Important disclosure information regarding the subject companies covered in this report is available at www.macquarie.com/disclosures.

#### **Analyst Certification:**

The views expressed in this research accurately reflect the personal views of the analyst(s) about the subject securities or issuers and no part of the compensation of the analyst(s) was, is, or will be directly or indirectly related to the inclusion of specific recommendations or views in this research. The analyst principally responsible for the preparation of this research receives compensation based on overall revenues of Macquarie Group Ltd ABN 94 122 169 279 (AFSL No. 318062) (MGL) and its related entities (the Macquarie Group) and has taken reasonable care to achieve and maintain independence and objectivity in making any recommendations.

#### **General Disclaimers:**

Macquarie Securities (Australia) Ltd; Macquarie Capital (Europe) Ltd; Macquarie Capital Markets Canada Ltd; Macquarie Capital Markets North America Ltd; Macquarie Capital (USA) Inc; Macquarie Capital Securities Ltd and its Taiwan branch; Macquarie Capital Securities (Singapore) Pte Ltd; Macquarie Securities (NZ) Ltd; Macquarie First South Securities (Pty) Limited; Macquarie Capital Securities (India) Pvt Ltd; Macquarie Capital Securities (Malaysia) Sdn Bhd; Macquarie Securities Korea Limited and Macquarie Securities (Thailand) Ltd are not authorized deposit-taking institutions for the purposes of the Banking Act 1959 (Commonwealth of Australia), and their obligations do not represent deposits or other liabilities of Macquarie Bank Limited ABN 46 008 583 542 (MBL) or MGL. MBL does not guarantee or otherwise provide assurance in respect of the obligations of any of the above mentioned entities. MGL provides a guarantee to the Monetary Authority of Singapore in respect of the obligations and liabilities of Macquarie Capital Securities (Singapore) Pte Ltd for up to SGD 35 million. This research has been prepared for the general use of the wholesale clients of the Macquarie Group and must not be copied, either in whole or in part, or distributed to any other person. If you are not the intended recipient you must not use or disclose the information in this research in any way. If you received it in error, please tell us immediately by return e-mail and delete the document. We do not guarantee the integrity of any e-mails or attached files and are not responsible for any changes made to them by any other person. MGL has established and implemented a conflicts policy at group level (which may be revised and updated from time to time) (the "Conflicts Policy") pursuant to regulatory requirements (including the FSA Rules) which sets out how we must seek to identify and manage all material conflicts of interest. Nothing in this research shall be construed as a solicitation to buy or sell any security or product, or to engage in or refrain from engaging in any transaction. In preparing this research, we did not take into account your investment objectives, financial situation or particular needs. Macquarie salespeople, traders and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions which are contrary to the opinions expressed in this research. Macquarie Research produces a variety of research products including, but not limited to, fundamental analysis, macro-economic analysis, quantitative analysis, and trade ideas. Recommendations contained in one type of research product may differ from recommendations contained in other types of research, whether as a result of differing time horizons, methodologies, or otherwise. Before making an investment decision on the basis of this research, you need to consider, with or without the assistance of an adviser, whether the advice is appropriate in light of your particular investment needs, objectives and financial circumstances. There are risks involved in securities trading. The price of securities can and does fluctuate, and an individual security may even become valueless. International investors are reminded of the additional risks inherent in international investments, such as currency fluctuations and international stock market or economic conditions, which may adversely affect the value of the investment. This research is based on information obtained from sources believed to be reliable but we do not make any representation or warranty that it is accurate, complete or up to date. We accept no obligation to correct or update the information or opinions in it. Opinions expressed are subject to change without notice. No member of the Macquarie Group accepts any liability whatsoever for any direct, indirect, consequential or other loss arising from any use of this research and/or further communication in relation to this research. Clients should contact analysts at, and execute transactions through, a Macquarie Group entity in their home jurisdiction unless governing law permits otherwise. The date and timestamp for above share price and market cap is the closed price of the price date. Close Price is the final price at which the security is traded in the relevant exchange on the date indicated.

#### Country-Specific Disclaimers:

Australia: În Australia, research is issued and distributed by Macquarie Securities (Australia) Ltd (AFSL No. 238947), a participating organisation of the Australian Securities Exchange. **New Zealand**: In New Zealand, research is issued and distributed by Macquarie Securities (NZ) Ltd, a NZX Firm. **Canada**: In Canada, research is prepared, approved and distributed by Macquarie Capital Markets Canada Ltd, a participating organisation of the

2 January 2012 3

Macquarie Research India Banks

Toronto Stock Exchange, TSX Venture Exchange & Montréal Exchange. Macquarie Capital Markets North America Ltd., which is a registered brokerdealer and member of FINRA, accepts responsibility for the contents of reports issued by Macquarie Capital Markets Canada Ltd in the United States and sent to US persons. Any person wishing to effect transactions in the securities described in the reports issued by Macquarie Capital Markets Canada Ltd should do so with Macquarie Capital Markets North America Ltd. The Research Distribution Policy of Macquarie Capital Markets Canada Ltd is to allow all clients that are entitled to have equal access to our research. United Kingdom: In the United Kingdom, research is issued and distributed by Macquarie Capital (Europe) Ltd, which is authorised and regulated by the Financial Services Authority (No. 193905). Germany: In Germany, this research is issued and/or distributed by Macquarie Capital (Europe) Limited, Niederlassung Deutschland, which is authorised and regulated by the UK Financial Services Authority (No. 193905). and in Germany by BaFin. France: In France, research is issued and distributed by Macquarie Capital (Europe) Ltd, which is authorised and regulated in the United Kingdom by the Financial Services Authority (No. 193905). Hong Kong & Mainland China: In Hong Kong, research is issued and distributed by Macquarie Capital Securities Ltd, which is licensed and regulated by the Securities and Futures Commission. In Mainland China, Macquarie Securities (Australia) Limited Shanghai Representative Office only engages in nonbusiness operational activities excluding issuing and distributing research. Only non-A share research is distributed into Mainland China by Macquarie Capital Securities Ltd. Japan: In Japan, research is issued and distributed by Macquarie Capital Securities (Japan) Limited, a member of the Tokyo Stock Exchange, Inc. and Osaka Securities Exchange Co. Ltd (Financial Instruments Firm, Kanto Financial Bureau (kin-sho) No. 231, a member of Japan Securities Dealers Association and Financial Futures Association of Japan and Japan Securities Investment Advisers Association). India: In India, research is issued and distributed by Macquarie Capital Securities (India) Pvt Ltd., 92, Level 9, 2 North Avenue, Maker Maxity, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051, India, which is a SEBI registered Stock Broker having membership with National Stock Exchange of India Limited (INB231246738) and Bombay Stock Exchange Limited (INB011246734). Malaysia: In Malaysia, research is issued and distributed by Macquarie Capital Securities (Malaysia) Sdn. Bhd. (Company registration number: 463469-W) which is a Participating Organisation of Bursa Malaysia Berhad and a holder of Capital Markets Services License issued by the Securities Commission. Taiwan: Information on securities/instruments that are traded in Taiwan is distributed by Macquarie Capital Securities Ltd, Taiwan Branch, which is licensed and regulated by the Financial Supervisory Commission. No portion of the report may be reproduced or quoted by the press or any other person without authorisation from Macquarie. Nothing in this research shall be construed as a solicitation to buy or sell any security or product. Thailand: In Thailand, research is issued and distributed by Macquarie Securities (Thailand) Ltd, a licensed securities company that is authorized by the Ministry of Finance, regulated by the Securities and Exchange Commission of Thailand and is an exchange member no. 28 of the Stock Exchange of Thailand. The Thai Institute of Directors Association has disclosed the Corporate Governance Report of Thai Listed Companies made pursuant to the policy of the Securities and Exchange Commission of Thailand, Macquarie Securities (Thailand) Ltd does not endorse the result of the Corporate Governance Report of Thai Listed Companies but this Report can be accessed at: <a href="http://www.thai-iod.com/en/publications.asp?type=4">http://www.thai-iod.com/en/publications.asp?type=4</a>. South Korea: In South Korea, unless otherwise stated, research is prepared, issued and distributed by Macquarie Securities Korea Limited, which is regulated by the Financial Supervisory Services. Information on analysts in MSKL is disclosed at http://dis.kofia.or.kr/fs/dis2/fundMgr/DISFundMgrAnalystPop.jsp?companyCd2=A03053&pageDiv=02. South Africa: In South Africa, research is issued and distributed by Macquarie First South Securities (Pty) Limited, a member of the JSE Limited. Singapore: In Singapore, research is issued and distributed by Macquarie Capital Securities (Singapore) Pte Ltd (Company Registration Number: 198702912C), a Capital Markets Services license holder under the Securities and Futures Act to deal in securities and provide custodial services in Singapore. Pursuant to the Financial Advisers (Amendment) Regulations 2005, Macquarie Capital Securities (Singapore) Pte Ltd is exempt from complying with sections 25, 27 and 36 of the Financial Advisers Act. All Singapore-based recipients of research produced by Macquarie Capital (Europe) Limited, Macquarie Capital Markets Canada Ltd, Macquarie First South Securities (Pty) Limited and Macquarie Capital (USA) Inc. represent and warrant that they are institutional investors as defined in the Securities and Futures Act. United States: In the United States, research is issued and distributed by Macquarie Capital (USA) Inc., which is a registered broker-dealer and member of FINRA. Macquarie Capital (USA) Inc., accepts responsibility for the content of each research report prepared by one of its non-US affiliates when the research report is distributed in the United States by Macquarie Capital (USA) Inc. Macquarie Capital (USA) Inc.'s affiliate's analysts are not registered as research analysts with FINRA, may not be associated persons of Macquarie Capital (USA) Inc., and therefore may not be subject to FINRA rule restrictions on communications with a subject company, public appearances, and trading securities held by a research analyst account. Any persons receiving this report directly from Macquarie Capital (USA) Inc. and wishing to effect a transaction in any security described herein should do so with Macquarie Capital (USA) Inc. Important disclosure information regarding the subject companies covered in this report is available at www.macquarie.com/research/disclosures, or contact your registered representative at 1-888-MAC-STOCK, or write to the Supervisory Analysts, Research Department, Macquarie Securities, 125 W.55th Street, New York, NY 10019. © Macquarie Group

<b>Auckland</b>	<b>Bangkok</b>	<b>Calgary</b> Tel: (1 403) 218 6650	<b>Denver</b>	Frankfurt	<b>Geneva</b>	Hong Kong
Tel: (649) 377 6433	Tel: (662) 694 7999		Tel: (303) 952 2800	Tel: (069) 509 578 000	Tel: (41) 22 818 7777	Tel: (852) 2823 3588
<b>Jakarta</b>	<b>Johannesburg</b> Tel: (2711) 583 2000	<b>Kuala Lumpur</b>	<b>London</b>	<b>Manila</b>	<b>Melbourne</b>	Montreal
Tel: (62 21) 515 1818		Tel: (60 3) 2059 8833	Tel: (44 20) 3037 2000	Tel: (63 2) 857 0888	Tel: (613) 9635 8139	Tel: (1 514) 925 2850
<b>Mumbai</b> Tel: (91 22) 6653 3000	<b>Munich</b> Tel: (089) 2444 31800	New York Tel: (1 212) 231 2500	<b>Paris</b> Tel: (33 1) 7842 3823	<b>Perth</b> Tel: (618) 9224 0888	<b>Seoul</b> Tel: (82 2) 3705 8500	<b>Shanghai</b> Tel: (86 21) 6841 3355
<b>Singapore</b> Tel: (65) 6601 1111	<b>Sydney</b> Tel: (612) 8232 9555	<b>Taipei</b> Tel: (886 2) 2734 7500	<b>Tokyo</b> Tel: (81 3) 3512 7900	<b>Toronto</b> Tel: (1 416) 848 3500		

Available to clients on the world wide web at www.macquarieresearch.com and through Thomson Financial, FactSet, Reuters, Bloomberg, CapitallQ and TheMarkets.com.

2 January 2012 4

# Macquarie **Equities Research**





## **Asia Research**

Head	of E	 Daca	arch

John O'Connell (Global Co – Head) David Rickards (Global Co – Head)	(612) 8232 7544 (612) 8237 1159
Chris Hunt (Asia – Head)	(852) 3922 1119
Tim Smart (Asia – Deputy Head)	(852) 3922 3565

#### **Automobiles/Auto Parts**

Janet Lewis (China)	(852) 3922 5417
Amit Mishra (India)	(9122) 6720 4084
Clive Wiggins (Japan)	(813) 3512 7856
Michael Sohn (Korea)	(82 2) 3705 8644

#### **Banks and Non-Bank Financials**

Ismael Pili (Asia, Hong Kong)	(852) 3922 4774
Victor Wang (China)	(852) 3922 1479
Mudit Painuly (India)	(9122) 6720 4083
Suresh Ganapathy (India)	(9122) 6720 4078
Nicolaos Oentung (Indonesia)	(6221) 2598 8366
Alastair Macdonald (Japan)	(813) 3512 7476
Chan Hwang (Korea)	(822) 3705 8643
Matthew Smith (Malaysia, Singapore)	(65) 6601 0981
Alex Pomento (Philippines)	(632) 857 0899
Jemmy Huang (Taiwan)	(8862) 2734 7530
Passakorn Linmaneechote (Thailand)	(662) 694 7728

#### Conglomerates

Alex Pomento (Philippines)	(632) 857 0899
Somesh Agarwal (Singapore)	(65) 6601 0840

#### **Consumer and Gaming**

Gary Pinge (Asia)	(852) 3922 3557
Linda Huang (China, Hong Kong)	(852) 3922 4068
Amit Mishra (India)	(9122) 6720 4084
Lyall Taylor (Indonesia)	(6221) 2598 8489
Toby Williams (Japan)	(813) 3512 7392
HongSuk Na (Korea)	(822) 3705 8678
Alex Pomento (Philippines)	(632) 857 0899
Somesh Agarwal (Singapore)	(65) 6601 0840
Brandon Chen (Taiwan)	(8862) 2734 7518
Best Waiyanont (Thailand)	(662) 694 7993

#### **Emerging Leaders**

Jake Lynch (China, Asia)	(8621) 2412 9007
Robert Burghart (Japan)	(813) 3512 7853
Makoto Egami (Japan)	(813) 3512 7879

#### Industrials

Janet Lewis (Asia)	(852) 3922 5417
Patrick Dai (China)	(8621) 2412 9082
Saiyi He (China)	(852) 3922 3585
Inderjeetsingh Bhatia (India)	(9122) 6720 4087
Alex Kong (Korea)	(822) 3705 8551
Juwon Lee (Korea)	(822) 3705 8661
Sunaina Dhanuka (Malaysia)	(603) 2059 8993
David Gambrill (Thailand)	(662) 694 7753

#### Insurance

Scott Russell (Asia, China)	(852) 3922 3567
Chung Jun Yun (Korea)	(822) 2095 7222

#### **Media and Internet**

 Jiong Shao (China, Hong Kong)
 (852) 3922 3566

 Steve Zhang (China, Hong Kong)
 (852) 3922 3578

 Nitin Mohta (India)
 (9122) 6720 4090

 Prem Jearajasingam (Malaysia)
 (603) 2059 8989

 Alex Pomento (Philippines)
 (632) 857 0899

#### Oil, Gas and Petrochemicals

James Hubbard (Asia)	(852) 3922 1226
Jal Irani (India)	(9122) 6720 4080
Polina Diyachkina (Japan)	(813) 3512 7886
Brandon Lee (Korea)	(822) 3705 8669
Sunaina Dhanuka (Malaysia)	(603) 2059 8993
Trevor Buchinski (Thailand)	(662) 694 7829

#### **Pharmaceuticals and Healthcare**

Abhishek Singhal (India)	(9122) 6720 4086
Eunice Bu (Korea)	(822) 2095 7223
Chinnarat Boonmahanark (Thailand)	(662) 694 7985

#### **Property**

Callum Bramah (Asia)	(852) 3922 4731
David Ng (China, Hong Kong)	(852) 3922 1291
Jeffrey Gao (China)	(8621) 2412 9026
Unmesh Sharma (India)	(9122) 6720 4092
Felicia Barus (Indonesia)	(6221) 2598 8480
Hiroshi Okubo (Japan)	(813) 3512 7433
Sunaina Dhanuka (Malaysia)	(603) 2059 8993
Alex Pomento (Philippines)	(632) 857 0899
Tuck Yin Soong (Singapore)	(65) 6601 0838
Elaine Cheong (Singapore)	(65) 6601 0839
Corinne Jian (Taiwan)	(8862) 2734 7522
Brandon Chen (Taiwan)	(8862) 2734 7518
Patti Tomaitrichitr (Thailand)	(662) 694 7727

#### Resources / Metals and Mining

Andrew Dale (Asia)	(852) 3922 3587
Graeme Train (China)	(8621) 2412 9035
Matty Zhao (Hong Kong)	(852) 3922 1293
Pelen Ji (China, Hong Kong)	(852) 3922 4741
Christina Lee (Hong Kong)	(852) 3922 3571
Rakesh Arora (India)	(9122) 6720 4093
Adam Worthington (Indonesia)	(852) 3922 4626
Polina Diyachkina (Japan)	(813) 3512 7886
Chak Reungsinpinya (Thailand)	(662) 694 7982

#### Technology

0,	
Jeffrey Su (Asia, Taiwan)	(8862) 2734 7512
Lisa Soh (China)	(852) 3922 1401
Nitin Mohta (India)	(9122) 6720 4090
Damian Thong (Japan)	(813) 3512 7877
David Gibson (Japan)	(813) 3512 7880
George Chang (Japan)	(813) 3512 7854
Jeff Loff (Japan)	(813) 3512 7851
Daniel Kim (Korea)	(822) 3705 8641
Andrew Chang (Taiwan)	(8862) 2734 7526
Daniel Chang (Taiwan)	(8862) 2734 7516
Kylie Huang (Taiwan)	(8862) 2734 7528
<u>-</u> '.	

#### **Telecoms**

Nathan Ramler (Asia)	(813) 3512 7875
Lisa Soh (China, Hong Kong)	(852) 3922 1401
Riaz Hyder (Indonesia)	(6221) 2598 8486
Prem Jearajasingam	
(Malaysia, Singapore)	(603) 2059 8989
Alex Pomento (Philippines)	(632) 857 0899
Joseph Quinn (Taiwan)	(8862) 2734 7519
Chinnarat Boonmahanark (Thailand)	(662) 694 7985

#### **Transport & Infrastructure**

Janet Lewis (Asia, Japan)	(852) 3922 5417
Nicholas Cunningham (Japan)	(813) 3512 6044
Sunaina Dhanuka (Malaysia)	(603) 2059 8993
Corinne Jian (Taiwan)	(8862) 2734 7522

#### **Utilities & Renewables**

Adam Worthington (Asia)	(852) 3922 4626
Inderjeetsingh Bhatia (India)	(9122) 6720 4087
Prem Jearajasingam (Malaysia)	(603) 2059 8989
Alex Pomento (Philippines)	(632) 857 0899

#### Commodities

Jim Lennon	(4420) 3037 4271
Duncan Hobbs	(4420) 3037 4497
Bonnie Liu	(65) 6601 0144
Graeme Train	(8621) 2412 9035
Rakesh Arora	(9122) 6720 4093

#### **Data Services**

Eric Yeung	(852) 3922 4077
Economics	

Peter Eadon-Clarke (Asia, Japan)	(813) 3512 7850
Richard Gibbs (Australia)	(612) 8232 3935
Paul Cavey (China)	(852) 3922 3570
Renee Chen (Hong Kong, Taiwan)	(852) 3922 3597
Tanvee Gupta (India)	(9122) 6720 3455

#### Quantitative / CPG

Gurvinder Brar (Global)	(4420) 3037 4036
Burke Lau (Asia)	(852) 3922 5494
Patrick Hansen (Japan)	(813) 3512 7876
Ayumu Kuroda (Japan)	(813) 3512 7569
Simon Rigney (Japan)	(813) 3512 7872

#### Strategy/Country

Peter Eadon-Clarke (Asia, Japan)	(813) 3512 7850
Chris Hunt (China, Hong Kong)	(852) 3922 1119
Jiong Shao (China)	(852) 3922 3566
Rakesh Arora (India)	(9122) 6720 4093
Nicolaos Oentung (Indonesia)	(6121) 2598 8366
David Gibson (Japan)	(813) 3512 7880
Chan Hwang (Korea)	(822) 3705 8643
Yeonzon Yeow (Malaysia)	(603) 2059 8982
Alex Pomento (Philippines)	(632) 857 0899
Conrad Werner (Singapore)	(65) 6601 0182
Daniel Chang (Taiwan)	(8862) 2734 7516
David Gambrill (Thailand)	(662) 694 7753

#### Find our research at

Macquarie: www.macquarie.com.au/research www.thomson.com/financial Reuters: Bloomberg: MAC GO Factset: http://www.factset.com/home.aspx www.capitaliq.com www.themarkets.com

Email macresearch@macquarie.com for access

### Asia Sales

#### **Regional Heads of Sales**

Robin Black (Asia)	(852) 3922 2074
Chris Gray (ASEAN)	(65) 6601 0288
Peter Slater (Boston)	(1 617) 598 2502
Jeffrey Shiu (China & Hong Kong)	(852) 3922 2061
Thomas Renz (Geneva)	(41) 22 818 7712
Andrew Mouat (India)	(9122) 6720 4100
JJ Kim (Korea)	(822) 3705 8799
Jason Lee (Malaysia)	(603) 2059 8888
Chris Gould (Malaysia)	(603) 2059 8888
Gino C Rojas (Philippines)	(632) 857 0861
Eric Roles (New York)	(1 212) 231 2559
Luke Sullivan (New York)	(1 212) 231 2507
Paul Colaco (New York)	(1 212) 231 2496
Sheila Schroeder (San Francisco)	(1 415) 762 5001
Miki Edelman (Taiwan)	(8862) 2734 7580

#### Regional Heads of Sales cont'd

Angus Kent (Thailand)	(662) 694 7601
Michael Newman (Tokyo)	(813) 3512 7920
Angus Innes (UK/Europe)	(44) 20 3037 4841
Rob Fabbro (UK/Europe)	(44) 20 3037 4865
Sean Alexander (Generalist)	(852) 3922 2101

#### **Regional Head of Distribution**

Justin Crawford (Asia) (852) 3922 2065

#### Sales Trading

Adam Zaki (Asia)	(852) 3922 2002
Yat Quan Tan (Hong Kong)	(852) 3922 2028
Phil Sellaroli (Japan)	(813) 3512 7837
Grace Lee (Korea)	(822) 3705 8601
Jonathan Seymour (Singapore)	(65) 6601 0202

#### Sales Trading cont'd

Mike Keen (Europe)	(44) 20 3037 4905
Chris Reale (New York)	(1 212) 231 2555
Marc Rosa (New York)	(1 212) 231 2555
Stanley Dunda (Indonesia)	(6221) 515 1555
Kenneth Cheung (Malaysia)	(603) 2059 8888
Michael Santos (Philippines)	(632) 857 0813
Isaac Huang (Taiwan)	(8862) 2734 7582
Dominic Shore (Thailand)	(662) 694 7707

#### **Alternative Strategies**

Convertibles - Roland Sharman	(852) 3922 2095
Depository Receipts - Seung-Jin Lee	(65) 6601 0203
Derivatives – Mark Holland	(852) 3922 2081